Monopar reports Q4/FY2023 net loss of $1.8M/$8.4M; MNPR-101 Phase 1 dosimetry trial to start

Monopar Therapeutics

Cash, equivalents and short-term investments $7.3M at Dec. 31, 2023; plus $3.2M from Q1 2024 ATM; runway through June 30, 2025.
Net loss Q4 2023: $1.8M ($0.12/shr) vs $2.9M ($0.22/shr) in Q4 2022; FY 2023: $8.4M ($0.61/shr) vs $10.5M ($0.83/shr) in FY 2022.
R&D expenses fell to $1.0M in Q4 2023 ($2.1M Q4 2022) and $5.6M for FY 2023 ($7.6M FY 2022), driven by Validive cost reductions.
MNPR-101-Zr Phase 1 dosimetry trial cleared by HREC in Australia; lead investigator Professor Rodney Hicks; enrollment imminent.
Preclinical data: MNPR-101-Ac-225 caused near-complete tumor elimination in triple-negative breast xenograft model after single dose.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Monopar Therapeutics reported fourth quarter and full year ended December 31, 2023 results: net income Net loss for the fourth quarter of 2023 was $1.8 million or $0.12 per share compared to $2.9 million or $0.22 per share.

Period: fourth quarter and full year ended December 31, 2023
Net income: Net loss for the fourth quarter of 2023 was $1.8 million or $0.12 per share compared to $2.9 million or $0.22 per share
Result: reported results

Exact text from the filing

Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

Monopar Therapeutics filing history →

Source: SEC EDGAR

accession 0001437749-24-009686

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.